Suhasini Lulla

发表

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer

M. Ellis, C. Osborne, H. Heslop, 2022, Therapeutic advances in medical oncology.

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients

H. Heslop, C. Rooney, M. Brenner, 2022, Haematologica.

37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains

H. Heslop, A. Leen, Ayumi Watanabe, 2021, Open Forum Infectious Diseases.

Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.

R. Krance, C. Ramos, S. Gottschalk, 2020, Blood.